Thus, numerous antiangiogenic molecules (e.g., the anti-vascular endothelial growth factor (VEGF) monoclonal antibodies bevacizumab) are currently used in the treatment of various cancers, including HCC, according to recent guidelines [12]. Here, VEGFA is linked to hepatocellular carcinoma.